• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Pr

  2026-05-09

  DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe enables precise plasma membrane labeling and neuronal tracing in both live and fixed cell workflows where aqueous probe compatibility is not required. Researchers should not use DiI for organelle-specific targeting or protocols requiring water solubility.

• Structure-Based Screening Identifies NSP15 Inhibitors in SAR

  2026-05-08

  This study used structure-based virtual screening and molecular dynamics to identify natural product inhibitors of SARS-CoV-2 NSP15, a viral endoribonuclease implicated in immune evasion. Thymopentin and oleuropein emerged as stable, high-affinity inhibitors, establishing a foundation for future antiviral development targeting NSP15.

• Endothelial STING-JAK1 Axis: Normalizing Tumor Vasculature

  2026-05-07

  This study uncovers a novel role of endothelial STING in activating JAK1/STAT signaling downstream of type I IFN, which normalizes tumor vasculature and facilitates CD8+ T cell infiltration. The findings refine our understanding of how STING agonists mediate antitumor immunity and highlight endothelial cells as critical effectors for vascular-immune crosstalk in cancer therapy.

• Irinotecan (SKU A5133): Reliable Cytotoxicity & Viability As

  2026-05-07

  This article addresses real laboratory challenges in cell viability and cytotoxicity assays, demonstrating how Irinotecan (SKU A5133) offers robust, data-backed solutions for DNA damage and apoptosis studies in colorectal cancer research. It provides scenario-driven guidance, protocol parameters, and candid product selection advice for scientists seeking reproducible, high-quality results with Irinotecan from APExBIO.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-05-06

  This study demonstrates that BRD4 inhibitors, including (+)-JQ1, significantly sensitize diverse cancer cell lines to erastin-induced ferroptosis by promoting ROS accumulation and downregulating FSP1. These findings clarify the epigenetic modulation of ferroptosis and suggest new therapeutic strategies for FSP1-dependent cancers.

• Structural and Functional Diversity of Cyclosporin Variants

  2026-05-06

  This study systematically compares the structural dynamics and mitochondrial effects of cyclosporin variants B–E, revealing that only variants with flexible backbones—similar to Cyclosporin A—effectively inhibit mitochondrial permeability transition pore (MPTP) opening. These findings illuminate the molecular basis for the functional specificity of cyclosporin congeners and refine our understanding of their bioactivity profiles in immunosuppression and mitochondrial research.

• Sulfo-NHS-SS-Biotin: Cleavable Biotinylation for Protein Lab

  2026-05-05

  Sulfo-NHS-SS-Biotin is a water-soluble, cleavable biotinylation reagent designed for selective protein labeling on primary amines, particularly at the cell surface. It enables reversible affinity capture and streamlines workflows requiring biotin removal. The reagent is not suitable for intracellular labeling or applications incompatible with disulfide cleavage.

• Z-DEVD-FMK: Mechanistic Insights and Assay Precision in Apop

  2026-05-05

  Explore the advanced mechanistic roles of Z-DEVD-FMK, a potent caspase-3 inhibitor, in apoptosis assay design and neuroprotection studies. This article reveals new evidence-backed perspectives linking molecular specificity to practical assay decisions for translational research.

• AR Heterogeneity Dictates Prostate Cancer Response to Enzalu

  2026-05-04

  This study provides clear evidence that heterogeneity in androgen receptor (AR) expression among prostate cancer cells underlies distinct biological behaviors and differential responses to castration and Enzalutamide therapy. By identifying and experimentally validating AR-dependent and AR-independent resistance mechanisms, the work highlights new therapeutic strategies for castration-resistant prostate cancer (CRPC) and demonstrates the necessity of considering AR status in both experimental models and clinical approaches.

• GLP-1 (9-36) amide: Antagonist Precision in GLP-1R Signaling

  2026-05-04

  GLP-1 (9-36) amide is a rigorously validated glucagon-like peptide-1 receptor antagonist used to dissect GLP-1 receptor signaling. Its high specificity and strictly controlled handling enable reproducible results in metabolic regulation and type 2 diabetes research.

• Valemetostat: Dual EZH1/2 Inhibition for Adult T-cell Leukem

  2026-05-03

  Valemetostat represents the first clinically approved dual inhibitor targeting EZH1 and EZH2, key epigenetic regulators implicated in aggressive adult T-cell leukemia/lymphoma (ATL). By addressing compensatory mechanisms in histone methylation, this approach demonstrates improved antitumor efficacy and offers a promising new direction for relapsed or refractory ATL management.

• EPZ5676: DOT1L Inhibitor Workflows for MLL Leukemia Research

  2026-05-02

  EPZ5676 is a next-generation DOT1L inhibitor offering unmatched selectivity and potency for dissecting epigenetic regulation in MLL-rearranged leukemia and beyond. This guide translates bench-proven protocols, advanced applications, and troubleshooting insights into actionable strategies for optimizing H3K79 methylation inhibition in translational research.

• Cefoperazone Sodium Salt: Optimizing Gram-Negative Resistanc

  2026-05-02

  Cefoperazone sodium salt empowers reliable, reproducible in vitro antimicrobial assays—especially where β-lactamase stability and robust activity against gram-negative bacilli are critical. This guide translates comparative data and real-world troubleshooting into actionable protocols for resistance profiling, biliary infection models, and advanced susceptibility workflows.

• SR-202 (PPAR Antagonist): Precision Tools for Adipogenesis a

  2026-05-01

  Explore how SR-202, a selective PPAR antagonist, enables precision in insulin resistance and obesity research. This in-depth analysis reveals unique assay opportunities and anti-inflammatory insights, setting the stage for advanced translational applications.

• Eltanexor (KPT-8602): Unlocking Nuclear Export for Cancer Tr

  2026-04-30

  Eltanexor (KPT-8602) represents a paradigm shift for cancer translational researchers by targeting XPO1-mediated nuclear export—a process central to the mislocalization of tumor suppressors and oncogenic signaling in hematologic and solid malignancies. This article provides a mechanistic deep dive, highlights key data from recent preclinical and translational studies in leukemia and colorectal cancer, and offers actionable protocol guidance. By contextualizing Eltanexor's distinct profile versus earlier XPO1 inhibitors and integrating new insights into Wnt/β-catenin pathway modulation, we chart a roadmap for leveraging this agent in advanced cancer research while clarifying its chemopreventive and cytotoxic potential.

454 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page